Your browser doesn't support javascript.
loading
Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma.
Calvente, Lourdes; Tremblay-LeMay, Rosemarie; Xu, Wei; Chan, Fong Chun; Hong, Michael; Zhang, Tong; Yhim, Ho-Young; Kuruvilla, John; Crump, Michael; Kukreti, Vishal; Prica, Anca; Regier, Dean; Marra, Marco A; Karsan, Aly; Steidl, Christian; Scott, David W; Sabatini, Peter; Kridel, Robert.
Afiliación
  • Calvente L; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Tremblay-LeMay R; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
  • Xu W; Department of Biostatistics, Princess Margaret Cancer Centre, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
  • Chan FC; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Hong M; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Zhang T; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
  • Yhim HY; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Kuruvilla J; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Crump M; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Kukreti V; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Prica A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Regier D; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Marra MA; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
  • Karsan A; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Steidl C; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Scott DW; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
  • Sabatini P; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
  • Kridel R; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Br J Haematol ; 190(6): 864-868, 2020 09.
Article en En | MEDLINE | ID: mdl-32510594
ABSTRACT
Despite continuing improvements in the management of classical Hodgkin lymphoma (cHL), relapse remains associated with a risk of lymphoma-related mortality. The biological composition of relapse tumour biopsies shows interpatient variability, which can be leveraged to design prognostic biomarkers. Here, we validated the RHL30 assay, a previously reported gene expression model in an independent cohort of 41 patients with relapsed cHL. Patients classified as high-risk by the RHL30 assay had inferior failure-free survival (FFS) after autologous stem cell transplantation (2-year FFS 41% vs. 92%, P = 0·035). The RHL30 model is a robust biomarker that risk-stratifies patients considered for autologous stem cell transplantation.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Biomarcadores de Tumor / Regulación Neoplásica de la Expresión Génica / Trasplante de Células Madre Hematopoyéticas / Perfilación de la Expresión Génica Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2020 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Biomarcadores de Tumor / Regulación Neoplásica de la Expresión Génica / Trasplante de Células Madre Hematopoyéticas / Perfilación de la Expresión Génica Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2020 Tipo del documento: Article País de afiliación: Canadá